FDA Accepts UCB’s sBLA for 2 mL Bimzelx Device
The U.S. Food and Drug Administration (FDA) also accepted a second sBLA from UCB for the bimekizumab-bkzx (Bimzelx, UCB) 2mL device. Today, one dose of Bimzelx in moderate-to-severe plaque psoriasis is administered as two 1mL injections. Approval of the 2mL device presentations would mean that patients would have an alternative dosing regimen, explains Jeffrey Stark, […]